Detalhe da pesquisa
1.
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.
Blood
; 141(16): 1971-1981, 2023 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36626583
2.
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors.
Haematologica
; 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38235512
3.
Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial.
Oncologist
; 28(12): e1259-e1267, 2023 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37338150
4.
Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003).
Cancer Immunol Immunother
; 72(9): 2991-3002, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37289256
5.
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.
Am J Hematol
; 98(11): 1742-1750, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37647123
6.
Long-term survival and portal vein patency with novel PVTT surgery approach in advanced HCC patients with Vp3/4 PVTT following combination therapy of TKIs and PD-1 inhibitors.
BMC Surg
; 23(1): 384, 2023 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38114938
7.
Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow-up of the multicenter, single-arm, Phase 2 study.
Int J Cancer
; 150(6): 984-992, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34674396
8.
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.
Cancer Immunol Immunother
; 71(8): 1897-1908, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34984540
9.
Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.
BMC Cancer
; 22(1): 403, 2022 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35418080
10.
Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study.
Ann Hematol
; 100(12): 2961-2968, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34331111
11.
Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma.
Chin J Cancer Res
; 33(5): 616-626, 2021 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-34815635
12.
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1.
Future Oncol
; 16(15): 991-999, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32250167
13.
Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors.
Oncologist
; 22(6): 638-e56, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28465370
14.
[Efficacy and safety of rituximab combined with CHOP or combined with dose fractionated CHOP in the treatment of primary gastric diffuse large B cell lymphoma].
Zhonghua Zhong Liu Za Zhi
; 36(12): 939-43, 2014 Dec.
Artigo
em Zh
| MEDLINE | ID: mdl-25623771
15.
Predicting central nervous system relapse in primary breast diffuse large B-cell lymphoma using the stage-modified IPI score: A retrospective cohort study.
Heliyon
; 10(5): e26795, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38439878
16.
Integrated Single Cell Analysis Reveals An Atlas of Tumor Associated Macrophages in Hepatocellular Carcinoma.
Inflammation
; 2024 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38668836
17.
High-purity isolation platelets by gradient centrifugation plus filtration.
Int J Lab Hematol
; 45(2): 187-194, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36470678
18.
IRF4 rearrangement may predict favorable prognosis in children and young adults with primary head and neck large B-cell lymphoma.
Cancer Med
; 12(9): 10684-10693, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37081786
19.
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial.
Clin Cancer Res
; 29(8): 1440-1449, 2023 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36735519
20.
Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study.
J Clin Oncol
; 41(16): 3032-3041, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36996373